Table 3.
Clinical estimates associated with erlotinib and chemotherapy treatment.
| Survival | Chemotherapy (Carboplatin + Pemetrexed) [18] | Erlotinib (EGFR Mutation Positive) [14] | Erlotinib (EGFR Wild Type) [14] |
|---|---|---|---|
| Mean duration of PFS (months) | 8.55 | 11.50 | 2.98 [19] |
| Grade 3–4 Adverse Events | |||
| Anemia | 7.7% | ||
| Arthralgia | 1.0% | 1.0% | |
| Diarrhea | 5.0% | 5.0% | |
| Fatigue | 7.7% | 6.0% | 6.0% |
| Febrile Neutropenia | 5.1% | ||
| Infection | 2.6% | ||
| Neuropathy | 1.0% | 1.0% | |
| Neutropenia | 25.6% | ||
| Pneumonitis | 1.0% | 1.0% | |
| Rash | 13.0% | 13.0% | |
| Stomatitis | 2.6% | ||
| Thrombocytopenia | 17.9% |
PFS = Progression-free survival; EGFR = Epidermal growth factor receptor.